Name: 글로벌 시장 동향
SKU: PH5034
Availability: InStock

보고서 요약(국문)

고처리량 스크리닝(HTS)은 자동화 장비를 사용하여 모델 생물, 세포, 경로 또는 분자 수준에서 수천에서 수백만 개의 샘플에 대한 생물학적 활성을 신속하게 테스트하는 기술입니다.
고처리량 스크리닝(HTS) 시장 동향 및 추세
전 세계 고처리량 스크리닝(HTS) 시장에 영향을 미치는 요인은 HTS의 장점 증가와 기술 발전이며, 이는 시장 성장을 견인할 것으로 예상됩니다.
HTS의 장점 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.
HTS는 기능적 또는 결합 분석에서 화합물을 동시에 테스트하는 데 필요합니다. HTS는 신약 개발 과정에서 많은 약물 유사 화합물의 생화학적 활성을 신속하게 스크리닝하는 데 사용됩니다. HTS 시스템의 핵심은 플레이트 또는 트레이로, 분석 시약과 샘플이 투입되고 반응이 모니터링되는 작은 웰로 구성됩니다. HTS 시스템은 하루에 수만 개, 심지어 수십만 개의 화합물을 평가할 수 있습니다. 처리량이 증가함에 따라 각 실험의 데이터 양도 증가하며, 과학자들은 방대한 양의 데이터를 분석하고 결과를 도출합니다. 처리되는 샘플 수가 많고 생성되는 데이터 양도 방대하기 때문에, 작업을 효율화하기 위해서는 광범위한 자동화 기술이 필요합니다. HTS의 장점 중 하나는 표적 단백질의 구조가 알려지지 않은 경우에도 사용할 수 있다는 점입니다.
또한, HTS는 단백질-단백질 상호작용 부위의 유도성 포켓과 알로스테릭 조절인자를 식별하는 데에도 사용될 수 있습니다. HTS 기술의 주요 목표는 하루 또는 주당 수천 개의 화합물을 스크리닝하여 대규모 화합물 라이브러리를 스크리닝함으로써 신약 개발을 가속화하는 것입니다. 병렬 및 조합 화학 합성을 통해 많은 새로운 화합물이 생성되기 때문입니다. HTS가 표적 특이적 화합물을 식별하는 데 효과적인 이유는 단일 메커니즘에 대한 레이저와 같은 집중력에 기인합니다. 이 기술의 발전은 화학 합성 전략의 변화와 밀접하게 관련되어 있습니다. 많은 과학자들이 조합 화학에 관심을 갖는 이유는 단기간에 많은 화합물을 생산하고 테스트할 수 있기 때문입니다. 화합물 식별에는 형광 공명 에너지 전달(FRET) 및 균일 시간 분해 형광(HTRF)과 같은 다양한 기술이 사용 가능합니다.

고처리량 스크리닝(HTS)과 관련된 한계점들이 시장 성장을 저해할 것으로 예상됩니다.
자동화는 기계 및 지원 인프라에 대한 대규모 투자를 필요로 하는데, 이는 중소 연구기관에는 부담이 됩니다. 결과적으로 자동화 기술과 관련된 높은 비용이 시장 성장을 저해할 수 있습니다. 또한, 호환되지 않는 라이브러리로 인한 낮은 히트율과 위양성 가능성 또한 단점입니다. HTS를 통해 PPI 억제제를 발굴한 가장 성공적인 사례 중 하나는 p53-MDM2 억제제인 버틀린(Butlin)과 벤조디아제핀디온(benzodiazepinediones)의 발견입니다. 버틀린 유도체인 RG7112는 현재 백혈병 및 고형암 치료를 위한 1상 임상시험 단계에 있습니다. 따라서 이러한 한계점들이 시장 성장을 저해할 것으로 예상됩니다.
COVID-19가 고처리량 스크리닝(HTS) 시장 성장에 미치는 영향
세계보건기구(WHO)가 COVID-19를 팬데믹으로 선언한 이후, 여러 유수의 제약 및 바이오제약 회사들이 치료제 개발에 나섰습니다. 불과 몇 주 만에 과학자들은 COVID-19를 표적으로 하는 분자 목록을 발견했습니다. 현재 79개의 백신 후보 물질이 개발 중이며, 그중 20개는 3상 임상 시험 단계에 있습니다. 여러 국가에서 현재까지 11개의 백신이 승인되었습니다. 렘데시비르, 클로로퀸 및 히드록시클로로퀸, 로피나비르 및 리토나비르, 그리고 로피나비르와 리토나비르에 인터페론 베타-1a를 병용한 요법 등 4가지 유망한 기존 약물이 COVID-19 치료제로 용도 변경되었습니다. 세계보건기구(WHO)는 2020년 3월 24일, 가장 유망한 COVID-19 치료제 4종에 대한 대규모 글로벌 임상 시험을 시작한다고 발표했습니다. 또한 여러 국가의 연구자들은 다양한 기존 약물의 COVID-19 치료 가능성을 연구하고 있습니다. 고처리량 스크리닝 제품이 신약 개발에 활용됨에 따라 COVID-19 치료제 개발을 위한 신약 개발 프로젝트가 증가하면서 시장이 성장할 것으로 예상됩니다.
고처리량 스크리닝(HTS) 시장 부문 및 점유율
최종 사용자 기준으로 제약 및 생명공학 부문이 시장 성장을 주도할 것으로 예상됩니다.
대부분의 대형 및 소형 생명공학 및 제약 회사는 지속 가능한 경쟁 우위를 확보하기 위해 다양한 만성 질환을 치료할 수 있는 새로운 분자 개발에 집중하고 있습니다. 또한, 미국 식품의약국(FDA) 산하 의약품 평가 연구 센터(CDER)의 신약 승인은 다양한 질환으로 고통받는 많은 환자들에게 도움을 주었습니다. 신약 개발 단계에서 여러 표적 분자를 신속하고 정확하게 스크리닝해야 하는 필요성 때문에 연구 과정에서 생성되는 방대한 화학 물질 및 바이오마커 라이브러리를 스크리닝하기 위한 자동화된 고처리량 스크리닝 기술의 도입이 증가했습니다. 자동화된
HTS 시스템은 하루에 10,000~100,000개의 표적 화합물을 테스트할 수 있고, uHTS는 하루에 100,000개 이상의 화합물을 테스트할 수 있기 때문에 신약 개발 과정에서의 활용이 증가하고 있습니다. 신약 개발은 새로운 항암제를 찾는 것을 목표로 하며, 이는 매우 복잡하고 다학제적인 과정입니다. 현재 신약 개발 프로토콜의 스크리닝 실패율을 보면 약 백만 개의 화합물을 스크리닝한 결과, 시장성 있는 신약이 하나 정도만 나오는 것으로 나타납니다. 따라서 파이프라인을 지속적으로 유지하고 고처리량 스크리닝(HTS)을 개발하기 위해 더 큰 규모의 라이브러리를 스크리닝하려는 요구가 커지고 있습니다. HTS는 실험실 자동화 기술의 특정 발전을 의미하며, 이를 통해 단시간에 대량의 실험 데이터를 수집할 수 있습니다. HTS를 사용하면 하루에 수십만 개의 화합물을 테스트할 수 있습니다. 따라서 제약 및 생명공학 산업에서 HTS의 활용이 시장 성장을 견인할 것으로 예상됩니다.
고처리량 스크리닝(HTS) 시장 지역 분석
북미 지역은 전 세계 고처리량 스크리닝(HTS) 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
이 지역의 HTS 시장 성장을 견인하는 요인으로는 질병 유병률 증가, 제약 R&D 지출 증가, 그리고 주요 기업들의 존재 등이 있습니다. 예를 들어, PerkinElmer, Inc.는 미국에 본사를 둔 다국적 기업입니다. 이 회사의 다중 모듈형 초고속 스크리닝 플랫폼은 초고속 스크리닝과 고함량 스크리닝(HCS)을 단일 플랫폼으로 결합한 독보적인 다중 모듈 시스템입니다. 따라서 이 지역에서 주요 업체들의 입지가 확대됨에 따라 시장 성장이 촉진될 것으로 예상됩니다.
고속 스크리닝(HTS) 기업 및 경쟁 환경
고속 스크리닝(HTS) 시장은 인수합병 및 신제품 출시가 활발하게 이루어지는 비교적 경쟁적인 시장입니다. 시장의 주요 업체로는 Agilent Technologies Inc., AYYam SpA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., Tecan Group Ltd, Hamilton Company, Aurora Biomed, Thermo Fisher Scientific Inc. 등이 있습니다.
Bio-Rad Laboratories Inc.
개요: Bio-Rad Laboratories, Inc.는 미국에 본사를 두고 있으며 생명 과학 연구 및 임상 진단 시장을 위한 특수 기술 제품을 개발 및 제조합니다. 이 회사는 1952년에 설립되었습니다.
제품 포트폴리오: ZE5 세포 분석기는 자동화가 가능한 고성능 유세포 분석기입니다. 고처리량 스크리닝 및 고차원 세포 분석 기능을 제공합니다.
주요 개발: 2020년 6월 30일, 바이오래드 연구소는 씨진과 감염성 질환 분자 진단 제품의 개발 및 상용화, 그리고 고처리량 스크리닝 시장에서의 입지 확대를 위한 파트너십을 체결했습니다.

보고서 요약(영어 원문)

High throughput screening rapidly tests thousands to millions of samples for biological activity at the model organism, cellular, pathway, or molecular level using automated equipment (HTS).
High-Throughput Screening (HTS) Market Dynamics and Trends
The factors influencing the global high-throughput screening (HTS) market are the increasing advantages and the growing technological advancements that are expected to drive market growth.
The increasing advantages of high-throughput screening (HTS) are expected to drive market growth in the forecast period
HTS is required to test the compounds in functional or binding assays simultaneously. HTS is used in the drug discovery process to quickly screen the biochemical activity of many drug-like compounds. A plate, or tray, is at the heart of the HTS system, consisting of tiny wells into which assay reagents and samples are deposited and their reactions monitored. In a single day, HTS systems can evaluate tens of thousands, if not hundreds of thousands, of compounds. The amount of data for each experiment grows as the throughput grows, and scientists analyze and derive results from large amounts of data. Because of the large number of samples processed and the large amount of data generated, extensive automation techniques are required to streamline operations. One of the benefits of HTS is that it can be used even if the structure of a target protein is unknown.
Furthermore, HTS can be used to identify inducible pockets in protein-protein interfaces and allosteric modulators. The primary goal of the HTS technique is to accelerate drug discovery by screening large compound libraries at a rate of a few thousand compounds per day or week. Because parallel and combinatorial chemical synthesis generates many novel compounds. HTS's effectiveness in identifying target-specific compounds can be attributed to its laser-like focus on a single mechanism. The evolution of this technology is closely linked to changes in chemical synthesis strategy. Many scientists are interested in combinatorial chemistry because of the large number of compounds that can be produced and the ability to test many compounds in a short period. Various techniques such as fluorescence resonance energy transfer (FRET) and homogeneous time-resolved fluorescence (HTRF) are available for compound identification.
Limitations associated with high-throughput screening (HTS) are expected to hamper the market growth
Automation necessitates large investments in machinery and supporting infrastructure, which is prohibitive for small and medium-sized research institutes. As a result, the high costs associated with automation techniques may stifle market growth. Moreover, the low hit rate due to incompatible libraries and the potential for false positives are both drawbacks. One of the most successful examples of identifying PPI inhibitors through HTS is the discovery of Butlins and benzodiazepinediones as p53–MDM2 inhibitors. RG7112, a nutlin derivative, is currently in Phase I clinical trials for the treatment of leukaemia and solid tumors. Hence, the limitations are expected to hamper the market growth.
COVID-19 Impact on High-Throughput Screening (HTS) Market Growth
Several established pharmaceutical and biopharmaceutical companies have stepped forward to develop treatments following the World Health Organization's declaration of the COVID-19 outbreak as a pandemic. In just a few weeks, scientists discovered a list of molecules that target COVID-19. There are currently 79 vaccine candidates in development, 20 of which are in stage 3 clinical trials. In several countries, 11 vaccines have been approved to date. Four promising drugs have been repurposed against COVID-19 (Remdesivir, Chloroquine & Hydroxychloroquine, Lopinavir & Ritonavir, and Lopinavir with Ritonavir plus Interferon beta-1a). The WHO announced on March 24, 2020, that it had started a global mega trial of the four most promising COVID-19 drugs. Furthermore, researchers in several countries are examining the potential of various existing drugs to treat COVID-19. With high-throughput screening products being used for drug discovery, the market is expected to grow due to increased drug discovery projects for the development of COVID-19 treatments.
High-Throughput Screening (HTS) Market Segment and Shares
Based on end-user, the pharmaceutical and biotechnology segment is expected to dominate the market growth
Most large and small biotechnology and pharmaceutical companies are focusing on developing novel molecules to treat a variety of chronic conditions to gain a sustainable competitive advantage. Furthermore, new drug therapy approvals by the FDA's Center for Drug Evaluation and Research (CDER) aided a wide range of patients suffering from various medical conditions. The adoption of automated high-throughput screening techniques to screen massive chemical and biomarker libraries generated during the research processes has resulted from the need for rapid and precise screening of several target molecules during the drug discovery and development phases. Because an automated
HTS system can test 10,000 to 100,000 target compounds per day, and uHTS can test more than 100,000 compounds per day, their use in the drug discovery and development process is growing. Drug discovery aims to find new antitumoral drugs, which is a highly complex and multidisciplinary process. The current drug discovery protocols' screening attrition rate suggests that one marketable drug emerges from approximately one million screened compounds. As a result, there is a push to screen larger libraries to keep the pipeline going and develop High Throughput Screening. HTS refers to specific developments in laboratory automation that allow for the collection of large amounts of experimental data in a short amount of time. Hundreds of thousands of compounds can be tested per day using HTS. Hence, the use of HTS in the pharmaceutical and biotechnology industry is expected to drive market growth.
High-Throughput Screening (HTS) Market Geographical Analysis
North America region is expected to hold the largest market share in the global high-throughput screening (HTS) market
The factors driving the growth of the HTS market in this region include rising disease prevalence, rising pharmaceutical R&D expenditure, and the presence of major players. For instance, PerkinElmer, Inc. is a multinational corporation based in the United States. The company's Ultra-High Throughput Screening Platform with Multiple Modules is a one-of-a-kind, multimodule system that combines ultra-high-throughput screening and high content screening (HCS) into a single platform. Hence, the growing presence of key players in this region is expected to boost market growth.
High-Throughput Screening (HTS) Companies and Competitive Landscape
High-Throughput Screening (HTS) Market is moderately competitive with mergers, acquisitions, and product launches. Some of the key players in the market are Agilent Technologies Inc., AYYam SpA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., Tecan Group Ltd, Hamilton Company, Aurora Biomed, Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Overview: Bio-Rad Laboratories, Inc. is based in the United States that develops and manufactures specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952.
Product Portfolio: The ZE5 Cell Analyzer is a high-performance flow cytometer that can be automated. It offers high-throughput screening and high-parameter cell analysis.
Key Development: On 30th June 2020, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc. to develop and commercialize infectious disease molecular diagnostic products, as well as to expand its presence in the high-throughput screening market.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet By Technology
3.2. Market Snippet By Application
3.3. Market Snippet By End User
3.4. Market Snippet By Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers:
4.1.1.1. The increasing advantages of high-throughput screening (HTS)
4.1.2. Restraints:
4.1.2.1. Limitations associated with high-throughput screening (HTS)
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before the COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or a Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Technology
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
7.3. Market Attractiveness Index, By Technology
7.3.1. Ultra-high-throughput Screening
7.3.1.1.
7.3.1.1.1. Introduction
7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3.2. Cell-based Assays
7.3.3. Lab-on-a-chip
7.3.4. Label-free Technology
7.3.5. Others
8. By Application
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
8.3. Market Attractiveness Index, By Application
8.3.1. Target Identification*
8.3.1.1.
8.3.1.1.1. Introduction
8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3.2. Primary Screening
8.3.3. Toxicology
8.3.4. Other
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Pharmaceutical and Biotechnology *
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Academia and Research Institutes
9.4. Other
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
12. Company Profiles
12.1. Bio-Rad Laboratories Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. Agilent Technologies Inc.
12.3. AYYam SpA
12.4. Beckman Coulter Inc.
12.5. Merck KGaA
12.6. PerkinElmer Inc.
12.7. Tecan Group Ltd
12.8. Thermo Fisher Scientific Inc.
12.9. Hamilton Company
12.10. Aurora Biomed(*LIST NOT EXHAUSTIVE)
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

언급된 주요 기업들

Bio-Rad Laboratories Inc., Agilent Technologies Inc., AYYam SpA, Beckman Coulter Inc., Merck KGaA, PerkinElmer Inc., Tecan Group Ltd, Thermo Fisher Scientific Inc., Hamilton Company

표 목록 (Tables)

List of Tables Table 01 Global High-Throughput Screening (HTS) Market, By Technology, 2022, 2026 & 2030 (US Million)

Table 02 Global High-Throughput Screening (HTS) Market, By Application, 2022, 2026 & 2030 (US Million)

Table 03 Global High-Throughput Screening (HTS) Market Value, By End User, 2022, 2026 & 2030 (US Million)

Table 04 Global High-Throughput Screening (HTS) Market Value, By Region, 2022, 2026 & 2030 (US Million)

Table 05 Global High-Throughput Screening (HTS) Market Value, By Technology, 2022, 2026 & 2030 (US Million)

Table 06 Global High-Throughput Screening (HTS) Market Value, By Technology, 2022, 2026 & 2030 (US Million)

Table 07 Global High-Throughput Screening (HTS) Market Value, By Application, 2022, 2026 & 2030 (US Million)

Table 08 Global High-Throughput Screening (HTS) Market Value, By Application, 2022-2030(US Million)

Table 09 Global High-Throughput Screening (HTS) Market Value, By End User, 2022, 2026 & 2030 (US Million)

Table 10 Global High-Throughput Screening (HTS) Market Value, By End User, 2022-2030(US Million)

Table 11 Global High-Throughput Screening (HTS) Market Value, By Region, 2022, 2026 & 2030 (US Million)

Table 12 Global High-Throughput Screening (HTS) Market Value, By Region, 2022-2030(US Million)

Table 13 North America High-Throughput Screening (HTS) Market Value, By Technology, 2022-2030(US Million)

Table 14 North America High-Throughput Screening (HTS) Market Value, By Application, 2022-2030(US Million)

Table 15 North America High-Throughput Screening (HTS) Market Value, By End User, 2022-2030(US Million)

Table 16 North America High-Throughput Screening (HTS) Market Value, By Country, 2022-2030(US Million)

Table 17 South America High-Throughput Screening (HTS) Market Value, By Technology, 2022-2030(US Million)

Table 18 South America High-Throughput Screening (HTS) Market Value, By Application, 2022-2030(US Million)

Table 19 South America High-Throughput Screening (HTS) Market Value, By End User, 2022-2030(US Million)

Table 20 South America High-Throughput Screening (HTS) Market Value, By Country, 2022-2030(US Million)

Table 21 Europe High-Throughput Screening (HTS) Market Value, By Technology, 2022-2030(US Million)

Table 22 Europe High-Throughput Screening (HTS) Market Value, By Application, 2022-2030(US Million)

Table 23 Europe High-Throughput Screening (HTS) Market Value, By End User, 2022-2030(US Million)

Table 24 Europe High-Throughput Screening (HTS) Market Value, By Country, 2022-2030(US Million)

Table 25 Asia-Pacific High-Throughput Screening (HTS) Market Value, By Technology, 2022-2030(US Million)

Table 26 Asia-Pacific High-Throughput Screening (HTS) Market Value, By Application, 2022-2030(US Million)

Table 27 Asia-Pacific High-Throughput Screening (HTS) Market Value, By End User, 2022-2030(US Million)

Table 28 Asia-Pacific High-Throughput Screening (HTS) Market Value, By Country, 2022-2030(US Million)

Table 29 Middle East & Africa High-Throughput Screening (HTS) Market Value, By Technology, 2022-2030(US Million)

Table 30 Middle East & Africa High-Throughput Screening (HTS) Market Value, By Application, 2022-2030(US Million)

Table 31 Middle East & Africa High-Throughput Screening (HTS) Market Value, By End User, 2022-2030(US Million)

Table 32 Bio-Rad Laboratories Inc.: Overview

Table 33 Bio-Rad Laboratories Inc.: Product Portfolio

Table 34 Bio-Rad Laboratories Inc.: Key Developments

Table 35 Agilent Technologies Inc.: Overview

Table 36 Agilent Technologies Inc.: Product Portfolio

Table 37 Agilent Technologies Inc.: Key Developments

Table 38 Axxam SpA: Overview

Table 39 Axxam SpA: Product Portfolio

Table 40 Axxam SpA: Key Developments

Table 41 Beckman Coulter Inc.: Overview

Table 42 Beckman Coulter Inc.: Product Portfolio

Table 43 Beckman Coulter Inc.: Key Developments

Table 44 Merck KGaA: Overview

Table 45 Merck KGaA: Product Portfolio

Table 46 Merck KGaA: Key Developments

Table 47 PerkinElmer Inc.: Overview

Table 48 PerkinElmer Inc.: Product Portfolio

Table 49 PerkinElmer Inc.: Key Developments

Table 50 Tecan Group Ltd: Overview

Table 51 Tecan Group Ltd: Product Portfolio

Table 52 Tecan Group Ltd: Key Developments

Table 53 Thermo Fisher Scientific Inc.: Overview

Table 54 Thermo Fisher Scientific Inc.: Product Portfolio

Table 55 Thermo Fisher Scientific Inc.: Key Developments

Table 56 Hamilton Company: Overview

Table 57 Hamilton Company: Product Portfolio

Table 58 Hamilton Company: Key Developments

Table 59 Aurora Biomed: Overview

Table 60 Aurora Biomed: Product Portfolio

Table 61 Aurora Biomed: Key Developments

그림 목록 (Figures)

List of Figures Figure 01 Global High-Throughput Screening (HTS) Market Share, By Technology, 2022 & 2030 (%)

Figure 02 Global High-Throughput Screening (HTS) Market Share, By Application, 2022 & 2030 (%)

Figure 03 Global High-Throughput Screening (HTS) Market Share, By End User, 2022 & 2030 (%)

Figure 04 Global High-Throughput Screening (HTS) Market Share, By Region, 2022 & 2030 (%)

Figure 05 Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 06 Global High-Throughput Screening (HTS) Market Y-o-Y Growth By Technology, 2022-2030 (%)

Figure 07 Ultra-high-throughput Screening: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 08 Cell-based Assays: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 09 Lab-on-a-chip: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 10 Label-free Technology: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 11 Others: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 12 Global High-Throughput Screening (HTS) Market Y-o-Y Growth By Application, 2022-2030 (%)

Figure 13 Target Identification: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 14 Primary Screening: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 15 Toxicology: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 16 Others: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 17 Global High-Throughput Screening (HTS) Market Y-o Y Growth By End User, 2022-2030 (%)

Figure 18 Pharmaceutical and Biotechnology : Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 19 Academia and Research Institutes: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 20 Other: Global High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 21 Global High-Throughput Screening (HTS) Market Y-o-Y Growth By Region, 2022-2030 (%)

Figure 22 North America High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 23 North America High-Throughput Screening (HTS) Market Share, By Technology, 2022 & 2030 (%)

Figure 24 North America High-Throughput Screening (HTS) Market Share, By Application, 2022 & 2030 (%)

Figure 25 North America High-Throughput Screening (HTS) Market Share, By End User, 2022 & 2030 (%)

Figure 26 North America High-Throughput Screening (HTS) Market Share, By Country, 2022 & 2030 (%)

Figure 27 South America High-Throughput Screening (HTS) Market Share, 2022-2030(US Million)

Figure 28 South America High-Throughput Screening (HTS) Market Share, By Technology, 2022 & 2030 (%)

Figure 29 South America High-Throughput Screening (HTS) Market Share, By Application, 2022 & 2030 (%)

Figure 30 South America High-Throughput Screening (HTS) Market Share, By End User, 2022 & 2030 (%)

Figure 31 South America High-Throughput Screening (HTS) Market Share, By Country, 2022 & 2030 (%)

Figure 32 Europe High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 33 Europe High-Throughput Screening (HTS) Market Share, By Technology, 2022 & 2030 (%)

Figure 34 Europe High-Throughput Screening (HTS) Market Share, By Application, 2022 & 2030 (%)

Figure 35 Europe High-Throughput Screening (HTS) Market Share, By End User, 2022 & 2030 (%)

Figure 36 Europe High-Throughput Screening (HTS) Market Share, By Country, 2022 & 2030 (%)

Figure 37 Asia-Pacific High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 38 Asia-Pacific High-Throughput Screening (HTS) Market Share, By Technology, 2022 & 2030 (%)

Figure39 Asia-Pacific High-Throughput Screening (HTS) Market Share, By Application, 2022 & 2030 (%)

Figure 40 Asia-Pacific High-Throughput Screening (HTS) Market Share, By End User, 2022 & 2030 (%)

Figure 41 Asia-Pacific High-Throughput Screening (HTS) Market Share, By Country, 2022 & 2030 (%)

Figure 42 Middle East & Africa High-Throughput Screening (HTS) Market Value, 2022-2030(US Million)

Figure 43 Middle East & Africa High-Throughput Screening (HTS) Market Share, By Technology, 2022 & 2030 (%)

Figure 44 Middle East & Africa High-Throughput Screening (HTS) Market Share, By Application, 2022 & 2030 (%)

Figure 45 Middle East & Africa High-Throughput Screening (HTS) Market Share, By End User, 2022 & 2030 (%)

Figure 46 Bio-Rad Laboratories Inc.: Financials

Figure 47 Agilent Technologies Inc.: Financials

Figure 48 Axxam SpA: Financials

Figure 49 Beckman Coulter Inc.: Financials

Figure 50 Merck KGaA: Financials

Figure 51 PerkinElmer Inc.: Financials

Figure 52 Tecan Group Ltd: Financials

Figure 53 Thermo Fisher Scientific Inc.: Financials

Figure 54 Hamilton Company: Financials

Figure 55 Aurora Biomed: Financials